PURPOSE: We describe a secondary effect of treatment with vigabatrin (VGB). A significant increase in alpha-aminoadipic acid (AAA) occurred in plasma and urine of VGB-treated children, thus mimicking a known rare metabolic disease, alpha-aminoadipic aciduria (AAAuria). METHODS: We studied eight children, aged from 3 months to 5 years, who were receiving VGB for drug-resistant partial epilepsies. Plasma and urine amino acids were assayed with ninhydrin detection on an automated Beckman 6300 analyzer. RESULTS: In eight out of eight children, there was a significant increase of AAA in plasma and in urine. Plasma values ranged from 7 to 8 microM (control values, < 5) and urinary values from 67 to 274 mmol/mol creatinine (control values, < 25). CONCLUSIONS: The concentrations of AAA in these VGB-treated children were as high as the concentrations found in the inherited metabolic disease, AAAuria. This could lead to incorrect diagnosis and to inappropriate genetic counseling. Thus whenever a genetic metabolic disease is suspected, amino acid chromatography testing should be performed before initiation of treatment with VGB.
PURPOSE: We describe a secondary effect of treatment with vigabatrin (VGB). A significant increase in alpha-aminoadipic acid (AAA) occurred in plasma and urine of VGB-treated children, thus mimicking a known rare metabolic disease, alpha-aminoadipic aciduria (AAAuria). METHODS: We studied eight children, aged from 3 months to 5 years, who were receiving VGB for drug-resistant partial epilepsies. Plasma and urine amino acids were assayed with ninhydrin detection on an automated Beckman 6300 analyzer. RESULTS: In eight out of eight children, there was a significant increase of AAA in plasma and in urine. Plasma values ranged from 7 to 8 microM (control values, < 5) and urinary values from 67 to 274 mmol/mol creatinine (control values, < 25). CONCLUSIONS: The concentrations of AAA in these VGB-treated children were as high as the concentrations found in the inherited metabolic disease, AAAuria. This could lead to incorrect diagnosis and to inappropriate genetic counseling. Thus whenever a genetic metabolic disease is suspected, amino acid chromatography testing should be performed before initiation of treatment with VGB.
Authors: João Leandro; Susmita Khamrui; Hui Wang; Chalada Suebsuwong; Natalia S Nemeria; Khoi Huynh; Moses Moustakim; Cody Secor; May Wang; Tetyana Dodatko; Brandon Stauffer; Christopher G Wilson; Chunli Yu; Michelle R Arkin; Frank Jordan; Roberto Sanchez; Robert J DeVita; Michael B Lazarus; Sander M Houten Journal: ACS Chem Biol Date: 2020-07-09 Impact factor: 5.100
Authors: Katharina Danhauser; Sven W Sauer; Tobias B Haack; Thomas Wieland; Christian Staufner; Elisabeth Graf; Johannes Zschocke; Tim M Strom; Thorsten Traub; Jürgen G Okun; Thomas Meitinger; Georg F Hoffmann; Holger Prokisch; Stefan Kölker Journal: Am J Hum Genet Date: 2012-11-08 Impact factor: 11.025
Authors: Dana C Walters; Erland Arning; Teodoro Bottiglieri; Erwin E W Jansen; Gajja S Salomons; Madalyn N Brown; Michelle A Schmidt; Garrett R Ainslie; Jean-Baptiste Roullet; K Michael Gibson Journal: Neurochem Int Date: 2019-02-26 Impact factor: 3.921
Authors: Dana C Walters; Erwin E W Jansen; Gajja S Salomons; Erland Arning; Paula Ashcraft; Teodoro Bottiglieri; Jean-Baptiste Roullet; K Michael Gibson Journal: Epilepsy Res Date: 2020-12-29 Impact factor: 3.045